Home Healthcare Pharmaceuticals Janus Kinases Inhibitor Drugs Market

Janus Kinases Inhibitor Drugs Market Size, Share & Trends Analysis Report By Type (JAK1 Inhibitors, JAK2 Inhibitors, JAK3 Inhibitors, Others), By Drug Type (Selective JAK Inhibitors, Non-selective JAK Inhibitors), By Indication (Autoimmune Diseases, Inflammatory Diseases, Dermatology, Oncology, Hematology), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: August 24, 2026 | Author: Dhanashri Chandgude | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Janus Kinases Inhibitor Drugs Market, By Type 2022-2034 (USD MILLION/ Units)
    1. JAK1 Inhibitors
    2. JAK2 Inhibitors
    3. JAK3 Inhibitors
    4. Others
  2. Janus Kinases Inhibitor Drugs Market, By Drug Type 2022-2034 (USD MILLION/ Units)
    1. Selective JAK Inhibitors
    2. Non-selective JAK Inhibitors
  3. Janus Kinases Inhibitor Drugs Market, By Indication 2022-2034 (USD MILLION/ Units)
    1. Autoimmune Diseases
      1. Rheumatoid Arthritis
      2. Psoriatic Arthritis
      3. Ankylosing Spondylitis
      4. Others
    2. Inflammatory Diseases
      1. Crohn's Disease
      2. Plaque Psoriasis
      3. Graft-versus-Host Disease
      4. Others
    3. Dermatology
      1. Atopic Dermatitis
      2. Vitiligo
      3. Alopecia Areata
      4. Others
    4. Oncology
    5. Hematology
  4. Janus Kinases Inhibitor Drugs Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. Others
  5. Regional Janus Kinases Inhibitor Drugs Market
    1. North America
      1. North America Janus Kinases Inhibitor Drugs Market By Type 2022-2034 (USD MILLION/ Units)
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
      2. North America Janus Kinases Inhibitor Drugs Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Selective JAK Inhibitors
        2. Non-selective JAK Inhibitors
      3. North America Janus Kinases Inhibitor Drugs Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        2. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        3. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        4. Oncology
        5. Hematology
      4. North America Janus Kinases Inhibitor Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
      5. U.S.
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      6. Canada
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
    2. Europe
      1. Europe Janus Kinases Inhibitor Drugs Market By Type 2022-2034 (USD MILLION/ Units)
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
      2. Europe Janus Kinases Inhibitor Drugs Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Selective JAK Inhibitors
        2. Non-selective JAK Inhibitors
      3. Europe Janus Kinases Inhibitor Drugs Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        2. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        3. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        4. Oncology
        5. Hematology
      4. Europe Janus Kinases Inhibitor Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
      5. U.K.
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      6. Germany
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      7. France
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      8. Spain
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      9. Italy
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      10. Russia
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      11. Nordic
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      12. Benelux
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      13. Rest of Europe
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
    3. APAC
      1. APAC Janus Kinases Inhibitor Drugs Market By Type 2022-2034 (USD MILLION/ Units)
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
      2. APAC Janus Kinases Inhibitor Drugs Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Selective JAK Inhibitors
        2. Non-selective JAK Inhibitors
      3. APAC Janus Kinases Inhibitor Drugs Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        2. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        3. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        4. Oncology
        5. Hematology
      4. APAC Janus Kinases Inhibitor Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
      5. China
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      6. Korea
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      7. Japan
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      8. India
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      9. Australia
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      10. Taiwan
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      11. South East Asia
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      12. Rest of Asia-Pacific
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
    4. Middle East and Africa
      1. Middle East and Africa Janus Kinases Inhibitor Drugs Market By Type 2022-2034 (USD MILLION/ Units)
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
      2. Middle East and Africa Janus Kinases Inhibitor Drugs Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Selective JAK Inhibitors
        2. Non-selective JAK Inhibitors
      3. Middle East and Africa Janus Kinases Inhibitor Drugs Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        2. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        3. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        4. Oncology
        5. Hematology
      4. Middle East and Africa Janus Kinases Inhibitor Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
      5. UAE
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      6. Turkey
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      7. Saudi Arabia
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      8. South Africa
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      9. Egypt
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      10. Nigeria
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      11. Rest of MEA
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
    5. LATAM
      1. LATAM Janus Kinases Inhibitor Drugs Market By Type 2022-2034 (USD MILLION/ Units)
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
      2. LATAM Janus Kinases Inhibitor Drugs Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Selective JAK Inhibitors
        2. Non-selective JAK Inhibitors
      3. LATAM Janus Kinases Inhibitor Drugs Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        2. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        3. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        4. Oncology
        5. Hematology
      4. LATAM Janus Kinases Inhibitor Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
      5. Brazil
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      6. Mexico
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      7. Argentina
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      8. Chile
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      9. Colombia
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
      10. Rest of LATAM
        1. JAK1 Inhibitors
        2. JAK2 Inhibitors
        3. JAK3 Inhibitors
        4. Others
        5. Selective JAK Inhibitors
        6. Non-selective JAK Inhibitors
        7. Autoimmune Diseases
          1. Rheumatoid Arthritis
          2. Psoriatic Arthritis
          3. Ankylosing Spondylitis
          4. Others
        8. Inflammatory Diseases
          1. Crohn's Disease
          2. Plaque Psoriasis
          3. Graft-versus-Host Disease
          4. Others
        9. Dermatology
          1. Atopic Dermatitis
          2. Vitiligo
          3. Alopecia Areata
          4. Others
        10. Oncology
        11. Hematology
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.